Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
